Article thumbnail

Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness

By Francesca Kum and Janaka Karalliedde


Increased central arterial stiffness, involving accelerated vascular ageing of the aorta, is a powerful and independent risk factor for early mortality and provides prognostic information above and beyond traditional risk factors for cardiovascular disease (CVD). Central arterial stiffness is an important determinant of pulse pressure; therefore, any pathological increase may result in left ventricular hypertrophy and impaired coronary perfusion. Central artery stiffness can be assessed noninvasively by measurement of aortic pulse wave velocity, which is the gold standard for measurement of arterial stiffness. Earlier, it was believed that changes in arterial stiffness, which are primarily influenced by long-term pressure-dependent structural changes, may be slowed but not reversed by pharmacotherapy. Recent studies with drugs that inhibit the renin–angiotensin–aldosterone system, advanced glycation end products crosslink breakers, and endothelin antagonists suggest that blood pressure (BP)-independent reduction and reversal of arterial stiffness are feasible. We review the recent literature on the differential effect of antihypertensive agents either as monotherapy or combination therapy on arterial stiffness. Arterial stiffness is an emerging therapeutic target for CVD risk reduction; however, further clinical trials are required to confirm whether BP-independent changes in arterial stiffness directly translate to a reduction in CVD events

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A comparison of atenolol and nebivolol in isolated systolic hypertension.
  2. Ageing of the conduit arteries.
  3. (2004). al; for British Hypertension Society. Guidelines for management of hypertension: report of the fourth Working Party of the British Hypertension Society, 2004-BHS IV . J Hum Hypertens.
  4. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients.
  5. (2003). Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int.
  6. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension.
  7. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease.
  8. (1996). Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens.
  9. Arterial stiffness.
  10. (1997). Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens.
  11. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
  12. (2006). Brachial and central arterial pressure. Hypertension.
  13. Brachial arterial pressure to assess cardiovascular structural damage: an overview and lessons from clinical trials.
  14. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension.
  15. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases.
  16. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
  17. Doxazosin reduces augmentation index but not pulse wave velocity in essential hypertension.
  18. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease.
  19. (2003). Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension.
  20. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
  21. European network for non-invasive investigation of large arteries expert consensus document on arterial stiffness: methodological issues and clinical applications.
  22. (2003). European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension.
  23. for REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/ indapamide combination in hypertensive patient: a comparison with atenolol.
  24. for the ASCEND Study Group. Avosentan for overt diabetic nephropathy.
  25. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.
  26. (2001). inflammation, hypertension, and cardiovascular disease. Curr Hypertens Rep.
  27. (1998). McDonald’s Blood Flow in Arteries: Theoretical Experimental and Clinical Principles.
  28. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo Cardiff Collaborative Trial (ACCT).
  29. O’Rourke M; for Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study
  30. (2005). pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol.
  31. (1997). Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol.
  32. Recent advances in arterial stiffness and wave reflection in human hypertension.
  33. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition.
  34. (1988). Reflected pressure waves in the ascending aorta: effect of glyceryl trinitrate. Cardiovasc Res.
  35. (1998). Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients.
  36. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part I: (patho)-physiology, rationale and perspective on pulse pressure amplification. Curr Pharm Des.
  37. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
  38. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
  39. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men.
  40. Wilkinson IB.Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.